|
Amphastar Pharmaceuticals, Inc. (AMPH) Évaluation DCF
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Amphastar Pharmaceuticals, Inc. (AMPH) Bundle
Explorez l'avenir financier d'Amphastar Pharmaceuticals, Inc. (AMPH) avec notre calculatrice DCF conviviale! Entrez vos projections pour la croissance, les marges et les dépenses pour déterminer la valeur intrinsèque d'Amphastar Pharmaceuticals, Inc. (AMPH) et améliorez votre stratégie d'investissement.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 322.4 | 349.8 | 437.8 | 499.0 | 644.4 | 768.1 | 915.5 | 1,091.3 | 1,300.8 | 1,550.5 |
| Revenue Growth, % | 0 | 8.53 | 25.13 | 13.98 | 29.14 | 19.2 | 19.2 | 19.2 | 19.2 | 19.2 |
| EBITDA | 81.5 | 30.2 | 111.8 | 107.5 | 240.3 | 181.7 | 216.6 | 258.1 | 307.7 | 366.7 |
| EBITDA, % | 25.27 | 8.63 | 25.53 | 21.54 | 37.29 | 23.65 | 23.65 | 23.65 | 23.65 | 23.65 |
| Depreciation | 21.1 | 25.2 | 26.8 | 28.7 | 41.8 | 49.3 | 58.8 | 70.1 | 83.5 | 99.6 |
| Depreciation, % | 6.55 | 7.2 | 6.11 | 5.76 | 6.48 | 6.42 | 6.42 | 6.42 | 6.42 | 6.42 |
| EBIT | 60.3 | 5.0 | 85.0 | 78.8 | 198.5 | 132.4 | 157.8 | 188.1 | 224.2 | 267.2 |
| EBIT, % | 18.72 | 1.43 | 19.42 | 15.78 | 30.81 | 17.23 | 17.23 | 17.23 | 17.23 | 17.23 |
| Total Cash | 85.4 | 105.6 | 136.7 | 175.8 | 256.8 | 250.3 | 298.4 | 355.7 | 424.0 | 505.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 45.4 | 66.0 | 78.8 | 88.8 | 114.9 | 133.0 | 158.5 | 189.0 | 225.2 | 268.5 |
| Account Receivables, % | 14.08 | 18.87 | 18 | 17.8 | 17.84 | 17.32 | 17.32 | 17.32 | 17.32 | 17.32 |
| Inventories | 110.5 | 96.8 | 92.8 | 103.6 | 105.8 | 184.9 | 220.4 | 262.6 | 313.1 | 373.2 |
| Inventories, % | 34.28 | 27.68 | 21.2 | 20.76 | 16.42 | 24.07 | 24.07 | 24.07 | 24.07 | 24.07 |
| Accounts Payable | 25.1 | 24.4 | 22.2 | 20.5 | 25.4 | 42.8 | 51.0 | 60.8 | 72.5 | 86.4 |
| Accounts Payable, % | 7.77 | 6.96 | 5.07 | 4.11 | 3.95 | 5.57 | 5.57 | 5.57 | 5.57 | 5.57 |
| Capital Expenditure | -41.6 | -33.9 | -27.5 | -24.0 | -38.2 | -60.8 | -72.5 | -86.4 | -103.0 | -122.7 |
| Capital Expenditure, % | -12.89 | -9.68 | -6.27 | -4.82 | -5.92 | -7.92 | -7.92 | -7.92 | -7.92 | -7.92 |
| Tax Rate, % | 19.73 | 19.73 | 19.73 | 19.73 | 19.73 | 19.73 | 19.73 | 19.73 | 19.73 | 19.73 |
| EBITAT | 49.0 | 1.2 | 62.8 | 62.0 | 159.3 | 89.4 | 106.6 | 127.0 | 151.4 | 180.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -102.2 | -15.2 | 51.1 | 44.2 | 139.5 | -1.8 | 40.1 | 47.8 | 57.0 | 67.9 |
| WACC, % | 6.93 | 6.24 | 6.84 | 6.9 | 6.92 | 6.77 | 6.77 | 6.77 | 6.77 | 6.77 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 165.5 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | 71 | |||||||||
| Terminal Value | 2,553 | |||||||||
| Present Terminal Value | 1,840 | |||||||||
| Enterprise Value | 2,006 | |||||||||
| Net Debt | 479 | |||||||||
| Equity Value | 1,526 | |||||||||
| Diluted Shares Outstanding, MM | 53 | |||||||||
| Equity Value Per Share | 28.80 |
What You Will Get
- Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to develop various scenarios.
- Real-World Data: Amphastar Pharmaceuticals’ financial data pre-filled to accelerate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you.
- Customizable and Professional: A refined Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.
Key Features
- Comprehensive AMPH Data: Pre-filled with Amphastar Pharmaceuticals’ historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Develop multiple forecast scenarios to evaluate various valuation outcomes.
- User-Friendly Design: Intuitive, structured, and suitable for both professionals and newcomers.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Amphastar Pharmaceuticals data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Amphastar Pharmaceuticals’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Amphastar Pharmaceuticals, Inc. (AMPH)?
- Accuracy: Utilizes real Amphastar financials to ensure precise data.
- Flexibility: Allows users to easily test and adjust inputs as needed.
- Time-Saving: Eliminate the complexity of creating a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected by CFOs.
- User-Friendly: Intuitive design makes it accessible for users without advanced financial modeling skills.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive and accurate valuation models for analyzing Amphastar Pharmaceuticals (AMPH).
- Pharmaceutical Finance Teams: Evaluate valuation scenarios to inform corporate strategies and investments.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Amphastar Pharmaceuticals (AMPH).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling related to the pharmaceutical sector.
- Industry Enthusiasts: Gain insights into how pharmaceutical companies like Amphastar (AMPH) are valued within the market.
What the Template Contains
- Pre-Filled Data: Contains Amphastar Pharmaceuticals' historical financials and projections.
- Discounted Cash Flow Model: Customizable DCF valuation model with automated calculations.
- Weighted Average Cost of Capital (WACC): A specific sheet for calculating WACC using tailored inputs.
- Key Financial Ratios: Examine Amphastar's profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth, profit margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.